《脊柱关节炎靶向药物治疗专家共识》要点解读

Interpretation on the Consensus on Targeted Drug Therapy for Spondyloarthritis

脊柱关节炎(spondyloarthritis,SpA)是一组以中轴骨和/或外周关节受累为主的慢性炎症性、致残性风湿免疫病,严重影响患者的身体功能和生活质量。随着靶向药物的临床应用越来越多,其精准且规范应用成为目前关注的重点。遵循共识制订的国际规范,国家皮肤与免疫疾病临床医学研究中心制定了我国首部《脊柱关节炎靶向药物治疗专家共识》,该共识对13个靶向药物应用过程中的重点问题作出推荐,涵盖了靶向药物治疗SpA的原则、适用人群、用药前筛查、用药时机、药物选择和转换、合并用药、不良反应监测等,并对特殊人群的用药注意事项提出建议,对临床实践具有重要指导意义。

Spondyloarthritis(SpA) is a group of chronic inflammatory diseases which predominantly involve spine and/or peripheral joints.SpA can be disabling and seriously affect the quality of life and function of patients.With the increasing clinical use of targeted drug therapy,precise and standardized use becomes the focus.China's first Consensus on Targeted Drug Therapy for Spondyloarthritis was developed by National Clinical Research Center for Dermatologic and Immunologic Diseases using international norms for consensus development.The consensus addresses 13 important clinical questions,ranging from principles,patient eligibility,pre-treatment screening,treatment initiation,drug selection and switch,co-medication,to adverse event monitoring of targeted drug therapy in SpA,and recommends treatment for specific patients,playing a key role in guiding clinical practices.